Most biz owners want to run deals but they have no idea how. They might slap a discount on a product in their store or put an ugly banner across the top of their site but they’re missing out on the INSANE CONVERSION POWER of a dedicated landing page for their deals.
Look, Groupon is charging local biz owners up to 90% on EVERY SALE THEY MAKE and the biz owner is ALREADY discounting their product or service by 50% or more leaving the biz owner with PEANUTS. Which is why You can easily charge $200 per month for a deals page and biz owners would be crazy if they didn’t SNAP IT UP in seconds.
In fact they’ll be probably be thanking you for saving them thousands per year on Groupon’s crippling commissions!With the click of a button, you can find businesses that are running deals on Yelp. This is a highly targeted market for local consultants. Video Embedding, Countdown timers, Limited Quantities and more to help your clients send their sales into overdrive.
The deals pages look awesome and work perfectly on any screen size or device.No coding, plugins or design tools. Create killer deals pages in a few simple clicks! Customize everything or just use the templates out of the box. Perfect for beginners or pros. Unlike most page builder tools, there’s zero monthly fees or hidden costs. And no hosting fees either!
On the surface, Eric Lefkofsky’s Tempus sounds much like every other AI-powered personalized medicine company. “We try to infuse as much data and technology as we can into the diagnosis itself,” Lefkofsky says, which could be said by the founder of any number of new healthcare companies.. But what makes Tempus different is that it is quickly branching out, moving from a focus on cancer to additional programs including mental health, infectious diseases, cardiology and soon diabetes. “We’re focused on those disease areas that are the most deadly,” Lefkofsky says.
Now, the billionaire founder has an additional $200 million to reach that goal. The Chicago-based company announced the series G-2 round on Thursday, which includes a massive valuation of $8.1 billion. Lefkofsky, the founder of multiple companies including Groupon, also saw his net worth rise from the financing, from an estimated $3.2 billion to an estimated $4.2 billion.
Tempus is “trying to disrupt a very large industry that is very complex,” Lefkofsky says, “we’ve known it was going to cost a lot of money to see our business model to fruition.”
In addition to investors Baillie Gifford, Franklin Templeton, Novo Holdings, and funds managed by T. Rowe Price, Lefkofsky, who has invested about $100 million of his own money into the company since inception, also contributed an undisclosed amount to the round. Google also participated as an investor, and Tempus says it will now store its deidentified patient data on Google Cloud.
“We are particularly attracted to companies that aim to solve fundamental and complex challenges within life sciences,” says Robert Ghenchev, a senior partner at Novo Holdings. “Tempus is, in many respects, the poster child for the kind of companies we like to support.”
Tempus, founded by Lefkofsky in 2015, is one of a new breed of personalized cancer diagnostic companies like Foundation Medicine and Guardant Health. The company’s main source of revenue comes from sequencing the genome of cancer patients’ tumors in order to help doctors decide which treatments would be most effective. “We generate a lot of molecular data about you as a patient,” Lefkofsky says. He estimates that Tempus has the data of about 1 in 3 cancer patients in the United States.
But billing insurance companies for sequencing isn’t the only way the company makes money. Tempus also offers a service that matches eligible patients to clinical trials, and it licenses de-identified patient data to other players in the oncology industry. That patient data, which includes images and clinical information, is “super important and valuable,” says Lefkofsky, who adds that such data sharing only occurs if patients consent.
At first glance, precision oncology seems like a crowded market, but analysts say there is still plenty of room for companies to grow. “We’re just getting started in this market,” says Puneet Souda, a senior research analyst at SVB Leerink, “[and] what comes next is even larger.” Souda estimates that as the personalized oncology market expands from diagnostics to screening, another $30 billion or more will be available for companies to snatch up. And Tempus is already thinking ahead by moving into new therapeutic areas.
While it’s not leaving cancer behind, Tempus has branched into other areas of precision medicine over the last year, including cardiology and mental health. The company now offers a service for psychiatrists to use a patient’s genetic information to determine the best treatments for major depressive disorder.
In May, Lefkofsky also pushed the company to use its expertise to fight the coronavirus pandemic. The company now offers PCR tests for Covid-19, and has run over 1 million so far. The company also sequences other respiratory pathogens, such as the flu and soon pneumonia. As with cancer, Tempus will continue to make patient data accessible for others in the field— for a price. “Because we have one of the largest repositories of data in the world,” says Lefkofsky, “[it is imperative] that we make it available to anyone.”
Lefkofsky plans to use capital from the latest funding round to continue Tempus’ expansion and grow its team. The company has hired about 700 since the start of the pandemic, he says, and currently has about 1,800 employees. He wouldn’t comment on exact figures, but while the company is not yet profitable he says Tempus has reached “significant scale in terms of revenue.”
And why is he so sure that his company’s massive valuation isn’t over-inflated? “We benefit from two really exciting financial sector trends,” he says: complex genomic profiling and AI-driven health data. Right now, Lefkofsky estimates, about one-third of cancer patients have their tumors sequenced in three years. Soon, he says, that number will increase to two-thirds of patients getting their tumors sequenced multiple times a year. “The space itself is very exciting,” he says, “we think it will grow dramatically.” Follow me on Twitter. Send me a secure tip.
I am the assistant editor of healthcare and science at Forbes. I graduated from UC Berkeley with a Master’s of Journalism and a Master’s of Public Health, with a specialty in infectious disease. Before that, I was at Johns Hopkins University where I double-majored in writing and public health. I’ve written articles for STAT, Vice, Science News, HealthNewsReview and other publications. At Forbes, I cover all aspects of health, from disease outbreaks to biotech startups.
To impact the nearly 1.7 million Americans who will be newly diagnosed with cancer this year, Eric Lefkofsky, co-founder and CEO of Tempus, discusses with Matter CEO Steven Collens how he is applying his disruptive-technology expertise to create an operating system to battle cancer. (November 29, 2016)
Google, which is primarily known for its search advertising business, is also trying to grow its display advertising business. Google has hundreds of partnerships with other websites, and its partner advertising product is known as ‘AdSense’. AdSense is an agreement involving Google providing advertising services to its partners and then sharing revenues with them.
One catalyst to the display ad business is the social buying phenomenon with companies like Groupon, which buys ads through AdSense. We estimate that AdSense accounts for around 5% of our $603 price estimate for Google stock. Our price is close to the market price.
Social buying phenomenon on the rise
Social buying is one of the hottest online trends these days where people share great deals in a group. Groupon, along with LivingSocial, are the leading companies to catch up with this trend. Groupon partners with businesses to offer consumers incredible savings on products and services.
Social deals create a win-win situation for both the consumers and the businesses. Consumers benefit from highly discounted deals while businesses benefit from a more focused and inexpensive advertising, and at the same time they increase their customer base.
However, the barriers to entry in this market are low, and players like Google, Yahoo, AOL and Facebook have jumped to tap into the growing social buying phenomenon — Google ‘Offers’ and Facebook ‘Deals’ are such examples. We touched upon this phenomenon, and how competition among these players has intensified, in our previous note titled “Yahoo Enters the Local Marketing Arena.”
How Groupon is benefiting Google?
We believe that the Groupon’s advertisement spend on AdSense is substantial. This can be determined from the fact that Groupon’s competitor LivingSocial spent $2.4 million on AdSense in June 2010 alone.  Moreover, LivingSocial has a much smaller reach than Groupon since it has a presence in far fewer countries and cities than Groupon.
Additionally, Groupon’s attractive business model means that its ads carry higher user click through rates, as many users tend to click on the discounted offers. Hence Groupon’s ads create higher monetization opportunities for Google AdSense program.
We estimate that AdSense program’s revenue per page view could increase from around $1.70 per 1,000 page views in 2010 to around $2.20 by the end of Trefis forecast period. However, although Groupon’s advertising spend on AdSense seems substantial, the benefit to Google stock is limited since AdSense contributes little to Google’s stock value.
Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company’s products, that you touch, read, or hear about everyday, impact its stock price. Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others. This might include you though you may have invested money in these companies, or may have been working with one of them for years as an employee, or have consulted with them as an expert for a long time. You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. The platform uses extensive data to show in a single snapshot what drives the value of a company’s business. Trefis is currently used by hundreds of thousands of investors, company employees, and business professionals.